ENXTPA:CLARIHealthcare
Clariane (ENXTPA:CLARI) Could Be 13% Undervalued Following Strong Half Year Results
Clariane (ENXTPA:CLARI) drew fresh attention after reporting half year 2026 results, highlighting higher operating EBITDA, lower net debt following a €1.063b bond issue, and reaffirmed medium term growth and margin objectives.
See our latest analysis for Clariane.
Clariane’s recent bond issue and half year 2026 earnings update arrived after a mixed period, with the share price up 3.05% year to date but the 1 year total shareholder return down 7.15%. This points to modest recent momentum while...